Close Menu

NEW YORK (GenomeWeb) – ArcherDx announced today that it has raised $60 million in a Series B financing round.

ArcherDx said it will use the proceeds from the funding round to scale operations and advance its companion diagnostic program, which includes solid tumors, hematological malignancies, and circulating tumor DNA applications. The firm will also use the funding to further expand its minimal residual disease (MRD) monitoring program.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.